BioNTech SE
BNTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, BioNTech SE (BNTX) is listed under Biotechnology. The $24.78B market capitalization puts BNTX squarely in large-cap range for its industry. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Market Cap
$24.78B
Beta
1.29
P/E (TTM)
—
P/E (Fwd)
-17.31
EPS (TTM)
$-7.77
EPS (Fwd)
$-5.70
ROE
-9.3%
ROA
-5.4%
Cash
$13.46B
Total Debt
$316.1M
Free CF
-$249.6M
52W Change
2.7%
Annual Financials
Cash vs Debt
Where BNTX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BNTX finished 7.33% above its 150-day moving average ($96.72) and 6.30% above its 200-day moving average ($97.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BNTX overbought or oversold?
At the September 3, 2026 close, BNTX's RSI(14) was 61.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $13.46B in cash comfortably exceeding the $316.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$249.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -9.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $17.31B (2022) to $2.87B (2025), a 83% decline worth watching.
With cash comfortably exceeding debt, BNTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing BNTX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.